Gendoo

MeSH keywords -> Related genes, diseases (OMIM)


Query MeSH keywords list

01 Drug Hypersensitivity [NCBI]


Gene


Gene Link Information
Gain
01
HLA-B [NCBI] 0.000118356
PTGS2 [NCBI] 0.000108116
CYSLTR1 [NCBI] 5.20829e-05
PTGS1 [NCBI] 5.01497e-05
CYP2C9 [NCBI] 3.07244e-05
CTAGE1 [NCBI] 2.82281e-05
XPNPEP2 [NCBI] 2.75625e-05
ENPP3 [NCBI] 2.70641e-05
LTC4S [NCBI] 2.69081e-05
FCER1A [NCBI] 2.67568e-05
VKORC1 [NCBI] 2.16923e-05
IFNG [NCBI] 2.02285e-05
IL4 [NCBI] 2.01234e-05
NAT2 [NCBI] 1.96493e-05
HLA-DRB1 [NCBI] 1.96405e-05
TBXA2R [NCBI] 1.86674e-05
IL4R [NCBI] 1.8656e-05
IL13 [NCBI] 1.82467e-05
HSPA1L [NCBI] 1.69156e-05
SMEK1 [NCBI] 1.48147e-05
CCT2 [NCBI] 1.48147e-05
TIPRL [NCBI] 1.48147e-05
CYP2C8 [NCBI] 1.44873e-05
HSPA1A [NCBI] 1.38741e-05
CYSLTR2 [NCBI] 1.24772e-05
CCT4 [NCBI] 1.24345e-05
CCT7 [NCBI] 1.24345e-05
SMEK2 [NCBI] 1.24345e-05
PPP4R1 [NCBI] 1.24345e-05
PPP4R2 [NCBI] 1.24345e-05
LACTB [NCBI] 1.15363e-05
PPP6C [NCBI] 1.15363e-05
EPHX1 [NCBI] 1.12268e-05
CCT6A [NCBI] 1.09531e-05
STAT6 [NCBI] 1.07146e-05
PPP4C [NCBI] 1.05195e-05
SLC35A1 [NCBI] 1.05195e-05
CCT3 [NCBI] 1.05195e-05
IGBP1 [NCBI] 1.05195e-05
PPP2CB [NCBI] 1.01741e-05
DCLRE1A [NCBI] 1.01741e-05
TFDP2 [NCBI] 1.01741e-05
CCT8 [NCBI] 1.01741e-05
DCLRE1B [NCBI] 1.01741e-05
HLA-C [NCBI] 1.00247e-05
IL10 [NCBI] 9.99617e-06
CIZ1 [NCBI] 9.88685e-06
RPS27A [NCBI] 9.42611e-06
CCT5 [NCBI] 9.42611e-06
TCP1 [NCBI] 8.90751e-06
RAD51L3 [NCBI] 8.51018e-06
IL21R [NCBI] 8.51018e-06
TPT1 [NCBI] 8.51018e-06
HLA-DQA1 [NCBI] 8.44474e-06
ITPA [NCBI] 8.09294e-06
GZMB [NCBI] 8.05005e-06
PPP2CA [NCBI] 7.75797e-06
AZGP1 [NCBI] 7.68359e-06
TBX21 [NCBI] 7.61233e-06
NEU1 [NCBI] 7.54393e-06
FIP1L1 [NCBI] 7.47818e-06
IFNGR1 [NCBI] 7.0779e-06
PTGER2 [NCBI] 7.02757e-06
DPEP1 [NCBI] 6.8853e-06
UBB [NCBI] 6.79669e-06
TNF [NCBI] 6.69309e-06
IFNGR2 [NCBI] 6.6719e-06
CYP2B6 [NCBI] 6.6719e-06
HLA-DRA [NCBI] 6.63227e-06
CCL24 [NCBI] 6.59355e-06
MS4A2 [NCBI] 6.41222e-06
XRCC2 [NCBI] 6.18723e-06
HLA-DQB1 [NCBI] 6.03297e-06
ALOX5 [NCBI] 5.91046e-06
RNASE3 [NCBI] 5.74074e-06
MPO [NCBI] 5.72902e-06
RYR1 [NCBI] 5.67297e-06
F9 [NCBI] 5.65097e-06
GSTP1 [NCBI] 5.46429e-06
HLA-DPB1 [NCBI] 5.22863e-06
EIF4EBP1 [NCBI] 4.86493e-06
CYP1A2 [NCBI] 4.79831e-06
ALOX5AP [NCBI] 4.68483e-06
CD1D [NCBI] 4.63682e-06
CAT [NCBI] 4.59757e-06
PIP [NCBI] 4.56734e-06
IL6 [NCBI] 4.36296e-06
AVP [NCBI] 4.3327e-06
CCR4 [NCBI] 4.19435e-06
SHC1 [NCBI] 4.03186e-06
SOCS3 [NCBI] 4.00766e-06
CXCL10 [NCBI] 4.00766e-06
JAK1 [NCBI] 3.79089e-06
CCR3 [NCBI] 3.77008e-06
NPHS1 [NCBI] 3.58805e-06
CD46 [NCBI] 3.51025e-06
NQO1 [NCBI] 3.45859e-06
CTSG [NCBI] 3.40315e-06
UGT1A1 [NCBI] 3.29792e-06
XRCC5 [NCBI] 3.23321e-06
MEFV [NCBI] 3.22834e-06
GAPDH [NCBI] 3.14333e-06
HNF1B [NCBI] 3.12054e-06
EGR1 [NCBI] 3.08478e-06
PRKDC [NCBI] 3.07598e-06
HLA-A [NCBI] 3.04125e-06
HNF1A [NCBI] 2.98236e-06
H2AFX [NCBI] 2.97824e-06
ALB [NCBI] 2.9257e-06
CCL11 [NCBI] 2.85214e-06
F8 [NCBI] 2.84836e-06
CYP3A4 [NCBI] 2.83337e-06
CCR5 [NCBI] 2.81853e-06
SLC2A1 [NCBI] 2.76419e-06
FAS [NCBI] 2.75709e-06
FASLG [NCBI] 2.75331e-06
FOXP3 [NCBI] 2.22583e-06
ESR1 [NCBI] 2.04041e-06
GSTT1 [NCBI] 2.00503e-06
CCL2 [NCBI] 1.97659e-06
GSTM1 [NCBI] 1.72751e-06
EGFR [NCBI] 1.3106e-06
CD68 [NCBI] 1.08144e-06
AKT1 [NCBI] 8.56407e-07
TGFB1 [NCBI] 6.2511e-07
EPO [NCBI] 5.1083e-07
VEGFA [NCBI] 4.43836e-07
PRL [NCBI] 3.7844e-07
PCNA [NCBI] 3.59655e-07




OMIM


OMIM Link Information
gain
01
ocular myopathy with curare sensitivity [NCBI] 0.00159179
asthma, nasal polyps, and aspirin intolerance [NCBI] 0.000508161
HLA-B [NCBI] 0.000422751
HSPA1L [NCBI] 0.000236905
CPAF [NCBI] 0.000163879
RNASE3 [NCBI] 0.000154515
mydriatic response to pharmacologic agents [NCBI] 0.000118236
LTC4S [NCBI] 9.92366e-05
craniosynostosis-microcephaly with chromosomal breakage and other abnormalities [NCBI] 9.57739e-05
MHS1 [NCBI] 9.46851e-05
SLE [NCBI] 9.00789e-05
EPHX1 [NCBI] 8.62119e-05
adie pupil [NCBI] 8.18052e-05
bronchiectasis [NCBI] 8.18052e-05
halothane hepatitis [NCBI] 6.94508e-05
deafness, aminoglycoside-induced [NCBI] 6.74301e-05
CIZ1 [NCBI] 6.49988e-05
DCLRE1B [NCBI] 6.49988e-05
RPS27A [NCBI] 6.49988e-05
severe cutaneous adverse reaction, susceptibility to [NCBI] 6.25585e-05
DCLRE1A [NCBI] 5.98009e-05
SCCMS [NCBI] 5.58151e-05
ITPA [NCBI] 5.39185e-05
PHF9 [NCBI] 5.19204e-05
TBX21 [NCBI] 5.19204e-05
GCE [NCBI] 4.85962e-05
CF [NCBI] 4.79103e-05
CYSLTR1 [NCBI] 4.75957e-05
CYP1A1 [NCBI] 4.70963e-05
ALOX5 [NCBI] 4.30113e-05
XRCC9 [NCBI] 4.10264e-05
BCPM [NCBI] 4.02885e-05
HLA-A [NCBI] 3.52958e-05
THPO [NCBI] 3.46508e-05
STAT6 [NCBI] 3.0421e-05
RNASE2 [NCBI] 2.81066e-05
RYR1 [NCBI] 2.74944e-05
IL6 [NCBI] 2.13202e-05
leber optic atrophy [NCBI] 1.93808e-05
MODY [NCBI] 1.72794e-05
hla-d histocompatibility type [NCBI] 1.63194e-05
CAT [NCBI] 1.55858e-05
GAPDH [NCBI] 1.24033e-05
ALB [NCBI] 1.12878e-05
thrombocytopenic purpura, autoimmune [NCBI] 9.67788e-06
AVP [NCBI] 9.34413e-06
MPO [NCBI] 6.05067e-06
FA [NCBI] 5.29229e-06
TYMS [NCBI] 5.07197e-06
G6PD [NCBI] 3.74342e-06
CRC [NCBI] 2.38572e-06
EGFR [NCBI] 2.07836e-06
CRH [NCBI] 1.67807e-06
TNF [NCBI] 4.97671e-07
RA [NCBI] 3.80521e-07
EPO [NCBI] 1.74974e-07
MG [NCBI] 3.21912e-08
PCNA [NCBI] 7.10831e-09
PRL [NCBI] 6.25105e-10




Database Center for Life Science